Robotic surgery hits 'milestone' with autonomous gallbladder removal
Medical robotics experts at Johns Hopkins and Stanford universities revealed in a new study they have "significantly" pushed the envelope on what is possible for robots to do in the operating room without human doctors at the controls, using artificial intelligence to teach them how to overcome unexpected obstacles during surgical procedures.
The study, published Wednesday in the journal Science Robotics, described how by using a newly developed AI platform called Surgical Robot Transformer-Hierarchy, or SRT-H, scientists were able to instruct robotic arms to perform eight ex vivo gallbladder procedures "with 100% accuracy" -- all completely autonomously with no human help.
SRT-H is the latest advancement in "computer vision," a field of AI that enables robots to "see" and interpret images and videos, much like humans do. The system was shown videos of human surgeons doing the same procedure on pigs and reinforced with natural language captions describing the tasks. It also can respond to human voice commands during procedures.
Most significantly, SRT-H showed an ability to self-correct when scientists threw it curve balls such as adding blood-like dyes that changed the appearance of the gallbladder and surrounding tissues. They reported it was still able to precisely perform tasks such as strategically placing clips and severing parts with scissors.
The results were deemed important because they appear to move medical science closer to the goal of making AI-powered robots reliable enough for "surgical autonomy," especially in routine procedures such as gallbladder removals, which are performed hundreds of thousands of time each year.
The study was led by medical roboticist Axel Krieger, an associate professor at JHU's Whiting School of Engineering, who in 2022 used an earlier AI-based system to autonomously perform the first small-incision, camera-guided surgical procedure on the soft tissue of a pig.
SRT-H "represents a fundamental shift from robots that can execute specific surgical tasks to robots that understand surgical procedures," Kreiger told UPI in emailed comments.
It makes several key technological advances, including eliminating the requirement that robots operate only on specially marked tissue within highly controlled environments.
"The SRT-H adapts to individual anatomical features in real-time, making decisions on the fly and self-correcting when things don't go as expected -- much like a human surgeon would," he said.
Also, because the system was built using the same machine learning architecture that powers ChatGPT, it allows the robot to be interactive.
"it can respond to spoken commands like 'grab the gallbladder head' or corrections like 'move the left arm a bit to the left,' and actually learn from this feedback during the procedure," Krieger said.
The researcher added the learning framework "trains the robot by watching videos of surgeries, similar to how medical students learn. This approach has proven robust enough that the robot performed unflappably across trials with the expertise of a skilled human surgeon, even during unexpected scenarios typical in real surgeries."
Other medical robotics experts contacted by UPI agreed the results are a notable achievement for the surgical robotics field but cautioned it's still a long road until the day the machines are deemed safe enough to operate autonomously on human patients.
Tamas Haidegger, a professor at Óbuda University in Budapest, Hungary, and technical lead of medical robotics research at its Antal Bejczy Center for Intelligent Robotics, said the results demonstrate that "landmark progress has emerged in autonomous surgical systems" in recent months.
The case for autonomous interventions is indeed "strengthening," but are we on the brink of breakthrough in autonomous robotic surgery? Yes and no, he answered.
"The employed SRT-H system presented capability for error correction and generalization, which may lead to scalability," Haidegger said. "This is major. A first baby-step."
The current experiments, however, "only represent embryonic advancement in the super-complex domain of human surgery," he said, comparing the development of autonomous robotic surgery to that of self-driving cars.
"In 2004, all participants failed in crossing the Mojave desert during the first DARPA challenge, yet by 2007, even the simulated urban environment was manageable for most of the systems. Yet, when this technology hit the road, significant shortcomings were revealed, starting with the incompleteness of road signs to changing weather conditions, and most importantly -- the unpredictability of other drivers.
"Variability in live human surgery -- such as individual anatomy and pathology, hemorrhage, physiological tissue movement and unmodelled tissue properties -- limits immediate clinical deployment of an autonomous system."
Meanwhile, a British expert who was not connected to the new study agreed that it "really highlights the art of the possible with AI and surgical robotics."
Danail Stoyanov, professor of robot vision at University College London's Department of Computer Science and co-director of the UCL Hawkes Institute, told UPI the field of computer vision is making "incredible advances" for surgical video, adding that the availability of open robotic platforms for such research "make it possible to demonstrate surgical automation."
He cautioned however, that "many other challenges remain to make this practical in real clinical use. Technically generalizing to clinical conditions remains very hard, and there are additional hurdles with medical device verification, safety, efficacy and, of course, cost and liability."
JHU's Krieger similarly noted the current study merely provides "proof of concept. Before any clinical application, we need extensive additional testing and regulatory approval to ensure patient safety remains the top priority."
That being said, the immediate next step is to "train and test the system on more types of surgeries and expand its capabilities to perform complete autonomous surgeries from start to finish.
"Currently, we've demonstrated success with a lengthy phase of gallbladder removal, but we want to broaden the system's surgical repertoire" to include procedures that would benefit from the robot's "consistent precision and ability to operate in challenging conditions where human factors like fatigue or tremor might be limiting factors," Krieger said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Scotiabank Raises Comcast (CMCSA) Price Target, Maintains Sector Perform Rating
Comcast Corporation (NASDAQ:CMCSA) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. Scotiabank has nudged its price target on Comcast Corporation (NASDAQ:CMCSA) to $45 from $44.50, maintaining a rating on the stock. The adjustment reflects the bank's cautious optimism toward the broader Telecom, Media, and Technology (TMT) space as macroeconomic pressures intensify. A couple watching their favorite show on TV, enjoying the entertainment network service. In a note to clients, Scotiabank analysts described the TMT sector as a 'great place to hide' amid mounting global uncertainties, including slowing economic momentum and the impact of escalating tariff disputes. The firm sees companies like Comcast as relatively well-positioned to weather volatility, offering stability in a shifting landscape. While financial performance across the sector is expected to hold steady, Scotiabank flagged potential softness in key subscriber metrics. The bank pointed to slowing population growth, largely attributed to reduced immigration, as a factor that may weigh on new customer acquisition, particularly in broadband and wireless segments. Still, the firm sees Comcast's diversified portfolio, which spans broadband, content, and theme parks, as a buffer against near-term pressures. The modest target increase reflects both confidence in Comcast's earnings potential and caution over demographic headwinds. While we acknowledge the potential of CMCSA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
25 minutes ago
- Yahoo
AppLovin (APP) Reaffirmed as Top Pick by Citi Ahead of Q2 Earnings
Applovin Corporation (NASDAQ:APP) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. Applovin Corporation (NASDAQ:APP) shares jumped on Monday after Citi reiterated the stock as a top pick heading into the company's second-quarter earnings report, scheduled for August 6. The firm reaffirmed its Buy rating and maintained a $600 price target, citing confidence in AppLovin's performance and outlook. In a note to clients, Citi said it expects second-quarter results to come in at the high end of management's guidance ranges. The firm also highlighted strength in AppLovin's software platform and monetization strategy as key drivers of momentum heading into the second half of 2025 and into 2026. Citi's note emphasized that tailwinds from AI-driven ad targeting and growing demand for mobile app optimization tools continue to support revenue acceleration. With solid execution and rising visibility into long-term growth, Applovin Corporation (NASDAQ:APP) remains well-positioned in a competitive digital ecosystem. The company's upcoming earnings report will be closely watched for further signs of momentum, as investors look for confirmation of Citi's bullish stance and any upward revisions to guidance. While we acknowledge the potential of APP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
25 minutes ago
- Yahoo
JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 10, JPMorgan lowered its price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) from $30 to $28 but kept an 'Overweight' rating. JPMorgan highlighted that there is a 'valuation disconnect' and the current stock price does not fully reflect the long-term value of the company's business. A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has three FDA-approved treatments for Duchenne Muscular Dystrophy (DMD) with amenable mutations. These treatments are known as Exondys 51, Vyondys 53, and Amondys 45. Additionally, JPMorgan analysts noted that the company's gene therapy, Elevidys, has full approval for use in all ambulatory DMD patients. The company's gene therapy Elevidys currently has full approval for all ambulatory DMD patients, according to JPMorgan. However, Elevidys still holds accelerated approval status while Sarepta Therapeutics, Inc. (NASDAQ:SRPT) continues discussions with the FDA. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a medical research and drug development company focused on developing precision genetic medicines for rare diseases. The company has leading positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs). While we acknowledge the potential of SRPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data